AACR 2022 | Novel approaches for the treatment of myelofibrosis: navitoclax + ruxolitinib
Naveen Pemmaraju
• 11 Apr 2022
Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, gives a brief overview of novel treatment approaches in myelofibrosis (MF), drawing focus on a recent study investigating the use of navitoclax with ruxolitinib in patients with MF. Dr Pemmaraju highlights an ongoing study investigating this treatment combination, and thinking about disease modification in MF. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
